Cencora, Inc.

COR 10-Q · Q1 2026
API behind this page

COR Q1 2026 request

Playground key active
Request URL /api/financials?ticker=COR&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 85,932,016 81,487,060 +5.5%
Show Product Lines breakouts
Alliance Healthcare · International Healthcare Solutions 6,530,697 5,999,200 +8.9%
Animal Health · Corporate Non Segment 1,471,317 1,379,985 +6.6%
Other Healthcare Solutions · International Healthcare Solutions 1,093,276 959,695 +13.9%
Other non-strategic businesses · Corporate Non Segment 657,630 622,470 +5.6%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 7,623,973 6,958,895 +9.6%
U. S. Healthcare Solutions · Operating Segments 76,211,825 72,555,294 +5.0%
Show Consolidation Items breakouts
Corporate Non Segment 2,128,947 2,002,455 +6.3%
Intersegment Elimination -32,729 -29,584 -10.6%
Cost of Revenue 82,859,945 78,929,022 +5.0%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 6,834,551 6,194,653 +10.3%
U. S. Healthcare Solutions · Operating Segments 74,328,262 71,100,485 +4.5%
Show Consolidation Items breakouts
Corporate Non Segment 1,804,466 1,684,783 +7.1%
Intersegment Elimination -28,509 -27,860 -2.3%
Operating Segments 82,938,770 78,952,061 +5.0%
Gross Profit 3,072,071 2,558,038 +20.1%
Selling, General & Administrative 1,795,289 1,472,055 +22.0%
Depreciation Nonproduction 134,288 112,712 +19.1%
Amortization Of Intangible Assets 126,113 165,780 -23.9%
Litigation Settlement Expense -86,151 16,765 -613.9%
Show Consolidation Items breakouts
Material Reconciling Items -86,151 16,765 -613.9%
Business Combination Acquisition Related Costs 78,419 38,712 +102.6%
Show Consolidation Items breakouts
Material Reconciling Items 78,419 38,712 +102.6%
Show Business Acquisition breakouts
RCA · Equity units 42.1 — —
Restructuring Charges 14,166 45,760 -69.0%
Show Consolidation Items breakouts
Material Reconciling Items 14,166 45,760 -69.0%
Asset Impairment Charges 249,498 — —
Show Consolidation Items breakouts
Material Reconciling Items 249,498 — —
Operating Income 760,449 706,254 +7.7%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 142,156 165,180 -13.9%
U. S. Healthcare Solutions · Operating Segments 831,330 686,925 +21.0%
Show Consolidation Items breakouts
Corporate Non Segment 91,417 97,329 -6.1%
Intersegment Elimination -2,189 -126 -1637.3%
Operating Segments 1,062,714 949,308 +11.9%
Non-Operating Income (Expense) -20,600 57,874 -135.6%
Interest Income Expense Nonoperating Net 72,409 27,933 +159.2%
Income Before Taxes 708,640 620,447 +14.2%
Income Tax Expense (Benefit) 142,514 126,728 +12.5%
Net Income 566,126 493,719 +14.7%
Show Equity Components breakouts
Noncontrolling Interest 6,479 5,119 +26.6%
Retained Earnings 559,647 488,600 +14.5%
Net Income Loss Attributable To Noncontrolling Interest -6,479 -5,119 -26.6%
Net Income 559,647 488,600 +14.5%
EPS (Basic) 2.88 2.52 +14.3%
EPS (Diluted) 2.87 2.5 +14.8%
Wtd Avg Shares (Basic) 194,219 193,758 +0.2%
Wtd Avg Shares (Diluted) 195,319 195,188 +0.1%
Common Stock Dividends Per Share Declared 0.6 0.55 +9.1%
Operating Expenses 1,930,532 1,585,691 +21.7%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 647,266 599,062 +8.0%
U. S. Healthcare Solutions · Operating Segments 1,052,233 767,884 +37.0%
Show Consolidation Items breakouts
Corporate Non Segment 233,064 220,343 +5.8%
Intersegment Elimination -2,031 -1,598 -27.1%
Comprehensive Income 556,605 78,094 +612.7%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 1,753,122 3,224,260 -45.6%
Accounts Receivable 25,979,920 — —
Inventory 24,078,494 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 313,575 — —
Contract With Customer Asset Gross Current 1,661,822 1,192,707 +39.3%
Prepaid Expenses & Other Current Assets 678,218 515,923 +31.5%
Total Current Assets 54,151,576 49,986,634 +8.3%
Non-Current Assets
Property, Plant & Equipment 2,450,799 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 69,570 — —
Goodwill 13,730,761 — —
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 2,648,231 — —
U. S. Healthcare Solutions · Operating Segments 9,826,495 — —
Show Consolidation Items breakouts
Corporate Non Segment 1,256,035 — —
Deferred Tax Assets 206,821 219,417 -5.7%
Other Non-Current Assets 4,142,530 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 96,671 — —
Total Assets 78,361,214 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 918,693 — —
Intangible Assets (Q) — — —
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 3,328,642 3,333,662 -0.2%
Trade names and other 333,085 331,549 +0.5%
Other Assets
Intangible Assets Net Excluding Goodwill 3,678,727 3,682,211 -0.1%
Current Liabilities
Accounts Payable 56,063,820 49,910,853 +12.3%
Accrued Liabilities 2,726,043 2,385,026 +14.3%
Debt Current 342,276 2,213,226 -84.5%
Total Current Liabilities 59,132,139 54,509,105 +8.5%
Current Portion of Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
Alliance Healthcare debt 70,507 11,293 +524.3%
Multi-currency revolving credit facility due in 2030 220,000 1,665,900 -86.8%
Nonrecourse debt 51,769 36,124 +43.3%
Non-Current Liabilities
Long-Term Debt 7,579,459 5,935,321 +27.7%
Accrued Income Taxes Noncurrent 351,490 303,433 +15.8%
Deferred Tax Liabilities 1,635,670 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 11,386 — —
Litigation Reserve Noncurrent 3,868,883 4,296,902 -10.0%
Show Litigation Case breakouts
Opioid Lawsuits and Investigations 3.9 4.3 -9.3%
Other Non-Current Liabilities 3,697,605 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 72,331 — —
Long-Term Debt 7,921,735 — —
Show Debt Instrument breakouts
$1,000,000, 2.700% senior notes due 2031 994,118 — —
$500,000, 2.800% senior notes due 2030 497,327 — —
$500,000, 4.250% senior notes due 2045 495,846 — —
$500,000, 4.300% senior notes due 2047 494,154 — —
$500,000, 4.625% senior notes due 2027 497,615 — —
$500,000, 5.125% senior notes due 2034 495,251 — —
$600,000, 4.850% senior notes due 2029 596,804 — —
$700,000, 5.150% senior notes due 2035 695,048 — —
$750,000, 3.450% senior notes due 2027 748,360 — —
Alliance Healthcare debt 70,507 — —
Multi-currency revolving credit facility due in 2030 220,000 — —
Nonrecourse debt 150,541 — —
Term loan due in 2027 799,177 — —
€500,000, 2.875% senior notes due 2028 584,652 — —
€500,000, 3.625% senior notes due 2032 582,335 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 98,772 — —
Total Liabilities (Q) — — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 712,319 — —
Other Liabilities
Minority Interest 187,640 135,322 +38.7%
Stockholders' Equity
Common Stock 2,983 2,971 +0.4%
Additional Paid In Capital Common Stock 6,273,322 6,106,291 +2.7%
Retained Earnings 6,967,358 5,794,851 +20.2%
Accumulated Other Comprehensive Income -905,078 -1,399,624 +35.3%
Treasury Stock Common Value -10,430,257 -10,277,909 -1.5%
Total Stockholders' Equity 1,908,328 226,580 +742.2%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 2,095,968 361,902 +479.2%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -905,078 -1,399,624 +35.3%
Additional Paid In Capital 6,273,322 6,106,291 +2.7%
Common Stock 2,983 2,971 +0.4%
Noncontrolling Interest 187,640 135,322 +38.7%
Retained Earnings 6,967,358 5,794,851 +20.2%
Treasury Stock Common -10,430,257 -10,277,909 -1.5%
Total Liabilities & Equity 78,361,214 69,054,314 +13.5%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation 135,247 113,629 +19.0%
Adjustment For Amortization 129,024 167,843 -23.1%
Provision For Doubtful Accounts 13 3,871 -99.7%
Deferred Income Taxes 14,362 -5,077 +382.9%
Stock-Based Compensation 66,054 70,384 -6.2%
Inventory L I F O Reserve Period Charge -77,562 -7,324 -959.0%
Show Consolidation Items breakouts
Material Reconciling Items -77,562 -7,324 -959.0%
Inflationary Accounting Impact 8,723 7,666 +13.8%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 42,137 — —
Equity Investment Remeasurement Gain Loss -10,501 -3,480 -201.8%
Gain Loss On Sale Of Other Assets -35,816 — —
Other Non-Cash Items 6,726 7,047 -4.6%
Change in Accounts Receivable -830,752 -974,256 +14.7%
Change in Inventory -3,519,839 -1,655,165 -112.7%
Change in Prepaid & Other Assets -14,386 70,310 -120.5%
Change in Accounts Payable 1,307,868 -654,165 +299.9%
Increase Decrease In Accrued Liabilities -328,365 -338,130 +2.9%
Increase Decrease In Income Taxes Payable And Other Liabilities -13,726 -51,193 +73.2%
Net Cash from Operations -2,305,169 -2,718,782 +15.2%
Depreciation & Amortization 260,401 278,492 -6.5%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 35,815 33,361 +7.4%
U. S. Healthcare Solutions · Operating Segments 78,253 60,882 +28.5%
Show Consolidation Items breakouts
Corporate Non Segment 21,175 19,393 +9.2%
Investing Activities
Capital Expenditures -119,376 -105,893 -12.7%
Payments To Acquire Businesses Net Of Cash Acquired -219,686 -9,015 -2336.9%
Proceeds From Sale Of Other Productive Assets 43,057 — —
Payments To Acquire Equity Method Investments -10,710 -182,014 +94.1%
Other Investing Activities 7,400 -11,303 +165.5%
Net Cash from Investing -299,315 -343,039 +12.7%
Financing Activities
Proceeds From Issuance Of Debt 107,720 1,806,028 -94.0%
Repayments Of Long Term Debt -131,709 -44,950 -193.0%
Proceeds From Lines Of Credit 23,791,590 15,454,257 +53.9%
Repayments Of Lines Of Credit -23,501,389 -13,427,095 -75.0%
Proceeds From Stock Options Exercised 7,598 8,108 -6.3%
Payments Of Dividends Common Stock -126,516 -110,888 -14.1%
Tax Withholding for Share Compensation -98,151 -73,963 -32.7%
Proceeds From Payments For Other Financing Activities -5,939 -16,876 +64.8%
Net Cash from Financing 43,204 3,209,150 -98.7%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -24,576 -50,235 +51.1%
Net Change in Cash -2,585,856 97,094 -2763.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,808,693 3,394,974 -46.7%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 27,155 — —

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key